Skip to content

Alleviating Postoperative Pain after Laparoscopic Myomectomy: The Role of Dexamethasone and Ropivacaine in Superior Hypogastric Plexus Block

Alleviating Postoperative Pain after Laparoscopic Myomectomy: The Role of Dexamethasone and Ropivacaine in Superior Hypogastric Plexus Block

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078162
Enrollment
Unknown
Registered
2023-11-30
Start date
2023-11-30
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain after Laparoscopic Myomectomy

Interventions

Control Group:10ml: 100mg ropivacaine 20ml in the SHP area
Treatment Group:10ml: 100mg ropivacaine 19ml + 1ml: 5mg dexamethasone 1ml in the SHP area

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing elective laparoscopic myomectomy for uterine fibroids. 2.Number of fibroids not exceeding 10. 3.ASA grade of I-III. 4.Age between 18 to 55 years. 5.Willingness to participate in the study and provide signed informed consent. 6.Not currently participating in other clinical trials.

Exclusion criteria

Exclusion criteria: 1.Presence of other gynecological diseases, such as endometriosis, adenomyosis, cervical cancer, ovarian tumor, ovarian cyst, fallopian tube disease, vulvar cancer, and pelvic/abdominal adhesion. 2.Severe neurological disorders including Alzheimer's disease, Parkinson's disease, or epilepsy, and mental disorders such as anxiety or depression. 3.A history of diabetes mellitus, smoking, or alcohol abuse. 4.Long-term use of non-steroidal drugs, opioids, or other analgesic medications. 5.Chronic use of sedatives, hypnotics, or other psychiatric drugs. 6.Treatment with systemic glucocorticoids within the 4 weeks prior to surgery. 7.Allergy to trial drugs including ropivacaine and dexamethasone. 8.Inability to cooperate with the postoperative Visual Analogue Scale (VAS) score assessment.

Design outcomes

Primary

MeasureTime frame
VAS score;

Secondary

MeasureTime frame
cumulative consumption of non-steroidal anti-inflammatory drugs or opioids within 48 hours postoperatively;postoperative adverse reactions;intraoperative fluid volume, urine output, and blood loss;first postoperative exhaust time;first postoperative ambulation;

Countries

China

Contacts

Public ContactYing Zhang & Yingying Li

Affiliated Hospital of Guangdong Medical University

951902370@qq.com+86 156 2586 3613

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026